Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

Author(s): X.-L. Lu, X. Cao, X.-Y. Liu and B.-H. Jiao

Volume 17, Issue 12, 2010

Page: [1117 - 1124] Pages: 8

DOI: 10.2174/092986710790827861

Price: $65

Abstract

Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

Keywords: Protein tyrosine kinases, Src kinases, SH2, SH3, inhibitor, peptidomimetic, nonpeptide, progress

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy